Wells Fargo analyst Brandon Couillard initiated coverage of Myriad Genetics with an Overweight rating and $35 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
- Myriad Genetics price target raised to $34 from $29 at Scotiabank
- Myriad Genetics price target raised to $30 from $28 at Piper Sandler
- Myriad Genetics price target raised to $30 from $28 at TD Cowen
- Myriad Genetics price target raised to $29 from $25 at Guggenheim